{
    "hands_on_practices": [
        {
            "introduction": "A primary challenge in managing strongyloidiasis is detecting chronic, low-burden infections, where larval output is often scant and intermittent. Standard diagnostic methods like stool microscopy consequently suffer from low sensitivity. This exercise provides a quantitative foundation for a core clinical practice—serial specimen collection—by tasking you to calculate how repeating a test improves the overall probability of detection, a concept known as cumulative sensitivity . Understanding this principle is crucial for designing effective screening protocols.",
            "id": "4695833",
            "problem": "A pre-transplant screening program for Strongyloides stercoralis in patients at risk for hyperinfection syndrome relies on serial stool ova and parasite (O&P) examinations because the larval output can be intermittent. Suppose each stool O&P examination has a per-specimen sensitivity of $0.30$ for detecting Strongyloides stercoralis in an infected individual under routine laboratory conditions, and assume results across specimens are independent when collected on separate days. Using only foundational probability rules and the definition of sensitivity as the probability of a positive test given true infection, compute the cumulative sensitivity when collecting and testing three ($3$) independent stool specimens from an infected patient. Express your result as a decimal fraction and round your answer to four significant figures.",
            "solution": "The problem statement is deemed valid as it is scientifically grounded in the principles of diagnostic test evaluation and probability theory, well-posed with all necessary information provided, and objective in its formulation. It presents a realistic clinical scenario without contradictions or ambiguities.\n\nThe problem requires the calculation of the cumulative sensitivity of a screening protocol that involves three independent tests. Let $I$ represent the event that a patient is infected with *Strongyloides stercoralis*. The entire analysis is conditioned on this event.\n\nThe per-specimen sensitivity, denoted as $S_1$, is the probability of a single test being positive given that the patient is infected. The problem provides this value as:\n$$\nS_1 = P(\\text{Test is positive} | I) = 0.30\n$$\nThe number of independent stool specimens tested is $n=3$.\n\nThe cumulative sensitivity, which we will denote as $C_3$, is the probability of obtaining at least one positive result from the three tests, given that the patient is infected. This corresponds to the probability of the union of the events of each test being positive:\n$$\nC_3 = P(\\text{at least one of the 3 tests is positive} | I)\n$$\nTo calculate this, it is more direct to first calculate the probability of the complementary event: that all three tests are negative. Let $T_i^+$ and $T_i^-$ denote the events that the $i$-th test is positive and negative, respectively. The event \"at least one positive test\" is the complement of the event \"all tests are negative\", which is $(T_1^- \\cap T_2^- \\cap T_3^-)$.\n\nAccording to the law of total probability for complementary events:\n$$\nC_3 = 1 - P(T_1^- \\cap T_2^- \\cap T_3^- | I)\n$$\nThe probability that a single test is negative, given infection, is the complement of the sensitivity. This quantity is also known as the false negative rate.\n$$\nP(T_i^- | I) = 1 - P(T_i^+ | I) = 1 - S_1\n$$\nUsing the given value of $S_1$:\n$$\nP(T_i^- | I) = 1 - 0.30 = 0.70\n$$\nThe problem states that the test results are independent. Therefore, the probability that all three tests are negative is the product of the individual probabilities of each test being negative:\n$$\nP(T_1^- \\cap T_2^- \\cap T_3^- | I) = P(T_1^- | I) \\times P(T_2^- | I) \\times P(T_3^- | I)\n$$\n$$\nP(T_1^- \\cap T_2^- \\cap T_3^- | I) = (1 - S_1)^3 = (0.70)^3\n$$\nWe calculate this value:\n$$\n(0.70)^3 = 0.70 \\times 0.70 \\times 0.70 = 0.343\n$$\nNow, we substitute this result back into the expression for the cumulative sensitivity $C_3$:\n$$\nC_3 = 1 - 0.343 = 0.657\n$$\nThe problem requires the final answer to be expressed as a decimal fraction rounded to four significant figures. The calculated value $0.657$ currently has three significant figures (the digits $6$, $5$, and $7$). To express this with four significant figures, we must add a trailing zero, which is significant in this context.\n$$\nC_3 = 0.6570\n$$\nThis represents the cumulative sensitivity of the three-specimen testing protocol.",
            "answer": "$$\n\\boxed{0.6570}\n$$"
        },
        {
            "introduction": "Once strongyloidiasis progresses to severe illness, particularly in an immunocompromised patient, accurate clinical classification becomes vital for determining prognosis and guiding the intensity of treatment. The terms \"hyperinfection\" and \"dissemination\" describe distinct, albeit often overlapping, pathophysiological states with different implications. This problem challenges you to apply the precise, formal definitions of these syndromes to a classic clinical vignette, honing the diagnostic reasoning required to distinguish an accelerated autoinfective cycle from the ectopic migration of larvae .",
            "id": "4813497",
            "problem": "A $56$-year-old man who emigrated from a tropical region $20$ years ago presents with $3$ days of watery diarrhea, cough, and dyspnea. He started high-dose prednisone $2$ weeks ago for a flare of chronic obstructive pulmonary disease (COPD). On admission he is in shock requiring vasopressors; blood cultures grow Gram-negative rods. A stool agar plate culture shows migrating tracks with motile larvae consistent with Strongyloides species. Concentrated sputum microscopy reveals filariform larvae. Cerebrospinal fluid (CSF) analysis is unremarkable, and cerebrospinal fluid polymerase chain reaction (PCR) for Strongyloides deoxyribonucleic acid (DNA) is negative. No larvae are detected in urine or other sterile body fluids. \n\nUsing only fundamental definitions of the Strongyloides stercoralis life cycle and disease states, decide which classification best fits this presentation and why. The base facts to employ are: autoinfection is intrinsic to the life cycle; hyperinfection syndrome represents an increase in intrahost larval burden with amplification of the normal gastrointestinal–pulmonary migration; disseminated strongyloidiasis is defined by the presence of larvae in organs or body fluids not typically involved in the autoinfection route (for example, central nervous system (CNS), liver, kidney, or in blood, cerebrospinal fluid (CSF), or urine). Mucosal translocation of enteric bacteria can occur along migrating larvae and may cause Gram-negative bacteremia and shock.\n\nWhich option best classifies this case and justifies the classification?\n\nA. Hyperinfection syndrome without dissemination, because increased larval migration along the usual gastrointestinal–pulmonary route is evidenced by larvae in stool and sputum, and Gram-negative bacteremia can result from enteric translocation during hyperinfection; the absence of larvae in sites outside this route (for example, negative CSF) argues against dissemination.\n\nB. Disseminated strongyloidiasis without hyperinfection, because the presence of septic shock with Gram-negative bacteremia indicates hematogenous spread of larvae beyond the usual route, even if larvae are confined to stool and sputum.\n\nC. Both hyperinfection and dissemination, because sputum larvae prove hyperinfection and the concomitant Gram-negative bacteremia and shock establish dissemination, regardless of negative CSF findings.\n\nD. Neither hyperinfection nor dissemination, because larvae in sputum may be seen in chronic pulmonary colonization and the bacteremia is likely unrelated to Strongyloides migration.",
            "solution": "First principles and core definitions relevant to Strongyloides stercoralis disease states:\n\n1. Life cycle and autoinfection: Strongyloides stercoralis can complete an autoinfection cycle in the human host. Rhabditiform larvae in the intestine can develop into filariform larvae that penetrate the intestinal mucosa or perianal skin, enter the venous circulation, migrate to the lungs, ascend the tracheobronchial tree, and are swallowed back to the intestine. This gastrointestinal–pulmonary route is the normal autoinfection pathway, and it permits persistence for decades.\n\n2. Hyperinfection syndrome: Hyperinfection denotes an increase in the number of migrating larvae and an acceleration of the normal autoinfection cycle, typically precipitated by immunosuppression such as corticosteroids. Clinically, hyperinfection is characterized by increased larval burden in sites along the usual route (gastrointestinal tract and lungs), for example, abundant larvae in stool and sputum, and can be accompanied by severe gastrointestinal and pulmonary symptoms.\n\n3. Disseminated strongyloidiasis: Dissemination is defined by the presence of larvae in organs or body fluids not involved in the usual autoinfection pathway, such as the central nervous system (CNS), liver, kidney, or detection of larvae in blood, cerebrospinal fluid (CSF), or urine. While disseminated disease often coexists with hyperinfection in profoundly immunocompromised patients, the diagnostic criterion is larval presence outside the gastrointestinal–pulmonary axis.\n\n4. Bacterial translocation and sepsis: Migrating larvae can carry enteric bacteria transmurally and hematogenously, causing Gram-negative bacteremia and septic shock. The occurrence of Gram-negative bacteremia is a complication that can accompany hyperinfection or dissemination; however, bacteremia alone does not demonstrate larval presence in non-autoinfection sites.\n\nApply these principles to the case:\n\n- The patient has risk factors for hyperinfection (recent initiation of high-dose corticosteroids).\n- Stool agar culture with characteristic tracks and larvae indicates heavy intestinal larval output.\n- Sputum microscopy with filariform larvae provides direct evidence of larval migration along the pulmonary component of the normal autoinfection route, consistent with hyperinfection.\n- Gram-negative bacteremia and shock can be explained by bacterial translocation along migrating larvae and are not, by themselves, proof of dissemination.\n- There is no evidence that larvae are present in non-autoinfection sites: cerebrospinal fluid (CSF) polymerase chain reaction (PCR) is negative, and no larvae are reported in urine, blood, or other sterile compartments. Therefore, the defining criterion for dissemination is not met.\n\nThus, the best classification is hyperinfection syndrome without proven dissemination.\n\nOption-by-option analysis:\n\nA. Hyperinfection syndrome without dissemination, because increased larval migration along the usual gastrointestinal–pulmonary route is evidenced by larvae in stool and sputum, and Gram-negative bacteremia can result from enteric translocation during hyperinfection; the absence of larvae in sites outside this route (for example, negative CSF) argues against dissemination.\nEvaluation: This aligns with the definitions. The findings localize to the gastrointestinal–pulmonary pathway and there is no detection of larvae in non-autoinfection sites. Gram-negative bacteremia is an expected complication of hyperinfection via bacterial translocation and does not, on its own, establish dissemination. Verdict: Correct.\n\nB. Disseminated strongyloidiasis without hyperinfection, because the presence of septic shock with Gram-negative bacteremia indicates hematogenous spread of larvae beyond the usual route, even if larvae are confined to stool and sputum.\nEvaluation: This misinterprets bacteremia as proof of larval dissemination. Dissemination requires demonstration of larvae in non-autoinfection sites; bacteremia shows bacterial, not larval, spread. The presence of larvae in sputum, a usual-route site, supports hyperinfection rather than exclusive dissemination. Verdict: Incorrect.\n\nC. Both hyperinfection and dissemination, because sputum larvae prove hyperinfection and the concomitant Gram-negative bacteremia and shock establish dissemination, regardless of negative CSF findings.\nEvaluation: While sputum larvae support hyperinfection, bacteremia and shock do not fulfill the criterion for dissemination without evidence of larvae in extra–autoinfection sites (for example, CNS, urine, blood with larvae). Negative CSF testing and absence of larvae elsewhere argue against dissemination. Verdict: Incorrect.\n\nD. Neither hyperinfection nor dissemination, because larvae in sputum may be seen in chronic pulmonary colonization and the bacteremia is likely unrelated to Strongyloides migration.\nEvaluation: Chronic Strongyloides infection does not typically feature larvae in sputum; larval detection in sputum implies increased pulmonary migration consistent with hyperinfection. The temporal association with steroids and the known pathophysiology support a causal link to bacteremia via translocation. Verdict: Incorrect.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Preventing fatal hyperinfection syndrome in at-risk individuals slated for potent immunosuppression represents the pinnacle of clinical strategy in managing strongyloidiasis. This often requires making high-stakes decisions under significant time pressure, with incomplete diagnostic information. This final exercise simulates such a scenario, compelling you to synthesize epidemiological risk, the practical limitations of diagnostic tests (such as turnaround times), and the principles of preemptive therapy to construct a robust, life-saving screening and management protocol .",
            "id": "4695867",
            "problem": "A hospital inpatient is scheduled to receive pulse high-dose methylprednisolone at $1\\,\\mathrm{g}/\\mathrm{day}$ for $3$ consecutive days, starting in $48$ hours, for rapidly progressive immune-mediated nephritis. He is a $62$-year-old man who grew up in northeastern Thailand and immigrated $20$ years ago. He has not returned to Southeast Asia in >10 years. He recalls intermittent diarrhea in his youth but has no current gastrointestinal symptoms. His absolute eosinophil count is $0.1\\times 10^9/\\mathrm{L}$. Because glucocorticoids can precipitate Strongyloides stercoralis hyperinfection, the infectious diseases team is asked to design a stepwise screening protocol to minimize the risk of hyperinfection before steroids. The hospital laboratory can perform Enzyme-Linked Immunosorbent Assay (ELISA) serology for Strongyloides with a turnaround time of $5$–$7$ days, stool Polymerase Chain Reaction (PCR) with a turnaround of $36$ hours, and stool microscopy with a turnaround of $24$ hours per sample (single sample sensitivity is limited). The team also notes that Human T-lymphotropic Virus type $1$ (HTLV-$1$) status is unknown.\n\nStarting from fundamental definitions and well-tested facts about Strongyloides stercoralis autoinfection dynamics and the immunologic effects of systemic glucocorticoids, choose the protocol that most appropriately balances the probability of occult strongyloidiasis, the catastrophic risk of hyperinfection under imminent high-dose steroids, the performance and timelines of available tests, and the safety profile of preemptive therapy. The protocol must specify: immediate steps, tests and their sequence, decision points tied to laboratory turnaround relative to the steroid start time, and whether, when, and how to use empiric therapy if test results will not be available before steroids. Assume ivermectin at $200\\,\\mu\\mathrm{g}/\\mathrm{kg}$ per day is available, the patient is not pregnant, and there is no epidemiologic risk for *Loa loa*.\n\nWhich option is the best-designed protocol?\n\nA. Risk-stratify by epidemiology; order ELISA and three separate stool microscopy samples collected on consecutive days; defer steroids until all results return; do not give empiric therapy unless eosinophilia is present or stool microscopy is positive.\n\nB. Risk-stratify by epidemiology; if high risk and steroids must start within $48$ hours, draw Strongyloides ELISA serology immediately, send stool PCR now, and collect two stool specimens $12$–$24$ hours apart for microscopy; if no test result will return before the first steroid dose, initiate empiric ivermectin at $200\\,\\mu\\mathrm{g}/\\mathrm{kg}$ daily for $2$ days beginning immediately and proceed with steroids as scheduled; if HTLV-$1$ is positive or clinical concern for disseminated disease emerges, extend ivermectin to daily dosing until stool examinations are negative for $14$ consecutive days; repeat serology in $6$–$12$ months if initially negative to confirm clearance.\n\nC. Screen only with a complete blood count and proceed with steroids if the absolute eosinophil count is <$0.5\\times 10^9/\\mathrm{L}$; if eosinophilia is present, obtain a single stool microscopy and, regardless of turnaround, avoid empiric therapy and delay steroids until results are available.\n\nD. Order ELISA serology and start empiric albendazole at $400\\,\\mathrm{mg}$ once if serology turnaround exceeds $72$ hours; proceed with steroids without further stool testing; if serology returns negative, no further action is needed.",
            "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\n- **Patient Profile**: $62$-year-old man from northeastern Thailand, immigrated $20$ years ago, no return to Southeast Asia in >10 years.\n- **Past Medical History**: Intermittent diarrhea in youth.\n- **Current Status**: No current gastrointestinal symptoms. Absolute eosinophil count is $0.1\\times 10^9/\\mathrm{L}$. Human T-lymphotropic Virus type $1$ (HTLV-$1$) status is unknown. Not pregnant. No epidemiologic risk for *Loa loa*.\n- **Planned Treatment**: Pulse high-dose methylprednisolone at $1\\,\\mathrm{g}/\\mathrm{day}$ for $3$ consecutive days for rapidly progressive immune-mediated nephritis.\n- **Timeline**: Steroid treatment to start in $48$ hours.\n- **Available Laboratory Tests & Turnaround Times (TAT)**:\n    - Enzyme-Linked Immunosorbent Assay (ELISA) serology for *Strongyloides*: TAT $5$–$7$ days.\n    - Stool Polymerase Chain Reaction (PCR): TAT $36$ hours.\n    - Stool microscopy: TAT $24$ hours per sample. Single sample sensitivity is noted as limited.\n- **Available Medication**: Ivermectin at $200\\,\\mu\\mathrm{g}/\\mathrm{kg}$ per day.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is a clinical vignette that requires the application of principles from infectious diseases, immunology, and clinical pharmacology to devise a management strategy.\n\n- **Scientifically Grounded**: The problem is firmly rooted in established medical science.\n    - The link between glucocorticoid-induced immunosuppression and *Strongyloides stercoralis* hyperinfection is a well-documented and critical clinical concern.\n    - The patient's epidemiological profile (originating from northeastern Thailand) places him at high risk for chronic, asymptomatic strongyloidiasis, consistent with the parasite's known geographic distribution.\n    - The parasite's unique autoinfective life cycle, which allows it to persist for decades, explains the risk despite the patient having left the endemic area $20$ years ago.\n    - The description of available diagnostic tests (microscopy, serology, PCR) and their respective limitations (low sensitivity of microscopy, long TAT for serology) is accurate.\n    - The mention of HTLV-$1$ as a co-factor for severe strongyloidiasis is also a recognized phenomenon.\n    - The planned steroid dose ($1\\,\\mathrm{g}$ of methylprednisolone) is a very high dose, posing a significant risk for precipitating hyperinfection.\n- **Well-Posed**: The problem is well-posed. It provides all necessary information (patient risk factors, urgency of immunosuppression, available diagnostics with timelines, available therapy) to construct and evaluate a management protocol. The question asks to choose the \"best-designed protocol\" by balancing multiple competing factors (risks, benefits, timelines), which is a standard task in clinical decision-making.\n- **Objective**: The language is clear, precise, and objective. It presents clinical facts and laboratory data without subjective or biased phrasing.\n\n### Step 3: Verdict and Action\nThe problem is scientifically valid, well-posed, and objective. It is a realistic clinical scenario that can be solved by applying established medical principles. Therefore, a full solution will be derived.\n\n## SOLUTION DERIVATION\n\n### First Principles\n\n1.  ***Strongyloides stercoralis* Pathophysiology**: *S. stercoralis* is a nematode worm with a unique autoinfective life cycle. Filariform larvae can penetrate the intestinal mucosa or perianal skin to re-enter circulation and mature, establishing a cycle entirely within the host. This allows infection to persist for a lifetime, often asymptomatically, long after the individual has left an endemic area.\n2.  **Immune Control**: The host's cell-mediated immunity, particularly the T-helper $2$ (Th2) response involving eosinophils and IgE, is crucial for controlling the larval burden and preventing dissemination.\n3.  **Hyperinfection Syndrome**: Suppression of this cell-mediated immunity, classically by systemic glucocorticoids, can lead to uncontrolled multiplication of larvae. This results in hyperinfection syndrome, where larval load increases dramatically, and disseminated disease, where larvae migrate to ectopic sites (e.g., lungs, central nervous system) and can carry enteric bacteria, leading to polymicrobial bacteremia and sepsis. The mortality rate of hyperinfection syndrome is exceedingly high, often exceeding $50\\%$.\n4.  **Risk Assessment**: The patient is at high risk due to his origin in northeastern Thailand, a region highly endemic for *Strongyloides*. His history of immigration $20$ years ago is well within the latency period for this parasite. The absence of current symptoms or eosinophilia (his count is $0.1\\times 10^9/\\mathrm{L}$) does not rule out chronic infection.\n5.  **Diagnostic Evaluation**:\n    - **Serology (ELISA)**: High sensitivity ($>90\\%$), making it an excellent screening test to rule out infection. A negative result in a low-risk person is reassuring. A positive result in a high-risk person is highly suggestive of infection. Its major limitation here is the $5$–$7$ day turnaround, which is longer than the $48$-hour window before steroid initiation.\n    - **Stool Microscopy**: Specific if larvae are seen, but notoriously insensitive ($<50\\%$ even with multiple samples) for chronic, low-output infections. Relying on it to rule out infection is dangerous. TAT is $24$ hours per sample.\n    - **Stool PCR**: More sensitive than microscopy and highly specific. The TAT of $36$ hours makes it the most useful test for obtaining a rapid diagnosis before the $48$-hour deadline.\n6.  **Therapeutic Principle**: The risk of ivermectin therapy is very low in this patient (no *Loa loa* risk, not pregnant). In contrast, the risk of hyperinfection syndrome from high-dose steroids in an undiagnosed patient is catastrophic. Therefore, the principle of \"presumptive\" or \"empiric\" therapy is the standard of care when high-risk individuals require urgent, potent immunosuppression and definitive testing cannot be completed in time. Ivermectin is the drug of choice due to its high efficacy. Albendazole is significantly less effective.\n\n### Synthesis of an Optimal Protocol\n\nGiven the patient's high epidemiological risk and the imminent administration of high-dose steroids for a \"rapidly progressive\" condition, the protocol must prioritize preventing hyperinfection without unduly delaying the treatment for nephritis.\n\nAn optimal protocol would involve:\n1.  **Immediate parallel testing**: Order the best available tests simultaneously to maximize diagnostic yield. This includes stool PCR (for speed), serology (for sensitivity), and stool microscopy.\n2.  **Immediate empiric therapy**: Since the most sensitive test (serology) will not be back in time, and even the PCR (TAT $36$h) may not be available with certainty before the first steroid dose at $48$h, the safest course of action is to start empiric ivermectin ($200\\,\\mu\\mathrm{g}/\\mathrm{kg}/\\mathrm{day}$) immediately. A standard course for presumptive therapy is $2$ days.\n3.  **Proceed with steroids**: Once empiric antiparasitic therapy is initiated, it is safe to proceed with the scheduled methylprednisolone.\n4.  **Follow-up**: Review test results as they become available to confirm the diagnosis and guide any necessary extension of therapy (e.g., for confirmed or disseminated disease, or in the presence of HTLV-$1$ coinfection).\n\n### Option-by-Option Analysis\n\n**A. Risk-stratify by epidemiology; order ELISA and three separate stool microscopy samples collected on consecutive days; defer steroids until all results return; do not give empiric therapy unless eosinophilia is present or stool microscopy is positive.**\n\nThis protocol is deeply flawed.\n- `defer steroids until all results return`: The ELISA turnaround is $5$–$7$ days. Delaying treatment for a \"rapidly progressive immune-mediated nephritis\" for this long could lead to irreversible kidney failure. This poses an unacceptable risk.\n- `do not give empiric therapy unless eosinophilia is present or stool microscopy is positive`: This is dangerous. The patient has no eosinophilia. Stool microscopy is insensitive. This strategy would almost certainly lead to the patient receiving steroids without antiparasitic coverage, placing him at high risk for fatal hyperinfection.\n**Verdict: Incorrect.**\n\n**B. Risk-stratify by epidemiology; if high risk and steroids must start within $48$ hours, draw Strongyloides ELISA serology immediately, send stool PCR now, and collect two stool specimens $12$–$24$ hours apart for microscopy; if no test result will return before the first steroid dose, initiate empiric ivermectin at $200\\,\\mu\\mathrm{g}/\\mathrm{kg}$ daily for $2$ days beginning immediately and proceed with steroids as scheduled; if HTLV-$1$ is positive or clinical concern for disseminated disease emerges, extend ivermectin to daily dosing until stool examinations are negative for $14$ consecutive days; repeat serology in $6$–$12$ months if initially negative to confirm clearance.**\n\nThis protocol correctly balances all competing factors.\n- `Risk-stratify... high risk`: Correct.\n- `draw Strongyloides ELISA serology immediately, send stool PCR now, and collect... microscopy`: This is a comprehensive and appropriate \"shotgun\" approach to testing, using all available modalities in parallel.\n- `if no test result will return... initiate empiric ivermectin... immediately and proceed with steroids as scheduled`: This is the crucial, life-saving step. It rightly prioritizes preventing catastrophic hyperinfection with a safe empiric therapy, allowing the necessary treatment for nephritis to proceed on time. The drug, dose, and duration are correct for presumptive treatment.\n- `if HTLV-1 is positive or clinical concern for disseminated disease emerges, extend ivermectin`: This shows a sophisticated understanding of managing complicated strongyloidiasis, where longer courses are often needed.\n- `repeat serology in 6–12 months if initially negative to confirm clearance`: This clause is slightly oddly phrased. Typically, one would repeat a *positive* serology to document a fall in titer as evidence of successful treatment. Repeating a negative test to \"confirm clearance\" is not standard. However, this is a minor point concerning long-term follow-up and does not detract from the immediate, life-saving-actions of the protocol, which are perfectly designed. Among the choices, this protocol is overwhelmingly superior.\n**Verdict: Correct.**\n\n**C. Screen only with a complete blood count and proceed with steroids if the absolute eosinophil count is $<0.5\\times 10^9/\\mathrm{L}$; if eosinophilia is present, obtain a single stool microscopy and, regardless of turnaround, avoid empiric therapy and delay steroids until results are available.**\n\nThis protocol is negligent.\n- `Screen only with a complete blood count`: This is grossly insufficient. The absence of eosinophilia (a count $<0.5\\times 10^9/\\mathrm{L}$) is common in chronic strongyloidiasis and has very poor negative predictive value. The patient's count is $0.1\\times 10^9/\\mathrm{L}$, so this protocol would advise proceeding with steroids without any further action.\n- `delay steroids`: Same flawed logic as in option A.\n- `avoid empiric therapy`: This directly contradicts the standard of care for this high-risk scenario.\n**Verdict: Incorrect.**\n\n**D. Order ELISA serology and start empiric albendazole at $400\\,\\mathrm{mg}$ once if serology turnaround exceeds $72$ hours; proceed with steroids without further stool testing; if serology returns negative, no further action is needed.**\n\nThis protocol uses the wrong drug at an inadequate dose.\n- `start empiric albendazole`: Albendazole is known to be less effective than ivermectin for treating strongyloidiasis. Ivermectin is the clear drug of choice.\n- `at 400 mg once`: This is a completely ineffective dose. A single dose of albendazole is used for other soil-transmitted helminths, but for *Strongyloides*, the regimen is typically $400\\,\\mathrm{mg}$ twice daily for $7$ days, and even this is inferior to ivermectin. A single $400\\,\\mathrm{mg}$ dose would provide a false sense of security and would not be expected to prevent hyperinfection.\n- The protocol omits the faster and more sensitive tests like stool PCR.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}